Note 14 - Stockholders' Equity

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

14. Shareholders' Equity

Authorized Shares

We are authorized to issue an aggregate of 60,000,000 shares, all of which are designated as Common Stock having a par value of $0.375 per share. The Board of Directors is authorized to establish one or more series of preferred stock, setting forth the designation of each such series, and fixing the relative rights and preferences of each such series.

Accumulated Other Comprehensive Loss

The changes in components of accumulated other comprehensive loss, net of tax, are as follows:

	Foreign Currency Translation Adjustments			Pension and Postretirement Medical Benefits			Cash Flow Hedge			Total
December 31, 2019	$	(36.3	)	$	(0.7	)	$	(1.5	)	$	(38.5	)
Other comprehensive income (loss) before reclassifications		17.2			(1.0	)		(7.5	)		8.7
Amounts reclassified from accumulated other comprehensive loss		—			—			9.7			9.7
Net current period other comprehensive income (loss)		17.2			(1.0	)		2.2			18.4
December 31, 2020	$	(19.1	)	$	(1.7	)	$	0.7		$	(20.1	)
Other comprehensive (loss) income before reclassifications		(16.9	)		(0.4	)		10.8			(6.5	)
Amounts reclassified from accumulated other comprehensive loss		—			—			(11.3	)		(11.3	)
Net current period other comprehensive loss		(16.9	)		(0.4	)		(0.5	)		(17.8	)
December 31, 2021	$	(36.0	)	$	(2.1	)	$	0.2		$	(37.9	)

Accumulated other comprehensive loss associated with pension and postretirement benefits and cash flow hedges is included in Notes 13 and 11, respectively.

Repurchase of Common Stock

The Board of Directors has authorized the repurchase of 1,193,414 of our common stock. During the year ended December 31, 2021, the Company paid $15.0 million to repurchase 196,982 shares of its common stock at an average price of $76.13 per share. As of December 31, 2021, 1,193,414 shares were available to be repurchased. There were no share repurchases during the year ended December 31, 2020.